These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 8510320)

  • 41. [Combination effect of pazufloxacin and anti-mrsa drugs against beta-lactam antibiotic induced vancomycin-resistant MRSA (BIVR)].
    Yanagisawa C; Hanaki H; Oishi T; Uehara K; Yamaguchi Y; Matui H; Sunakawa K
    Jpn J Antibiot; 2005 Feb; 58(1):11-6. PubMed ID: 15847221
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model.
    Lee DG; Chun HS; Yim DS; Choi SM; Choi JH; Yoo JH; Shin WS; Kang MW
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3768-73. PubMed ID: 14638480
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1995)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kawaguchi H; Shimizu Y; Matsumiya H; Saito A; Terai T; Inoue H; Nakadate T; Ito C; Yosida T; Tanno Y; Ohno I; Nishioka K; Arakawa M; Igarashi K; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Touyama M
    Jpn J Antibiot; 1997 May; 50(5):421-59. PubMed ID: 9212366
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhancement of antimicrobial effects of various antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) by combination with fosfomycin.
    Nakazawa H; Kikuchi Y; Honda T; Isago T; Nozaki M
    J Infect Chemother; 2003 Dec; 9(4):304-9. PubMed ID: 14691650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Specificity of 4'''-acetylation by an aminoglycoside-modifying enzyme in arbekacin-resistant strains of methicillin-resistant Staphylococcus aureus.
    Fujimura S; Tokue Y; Takahashi H; Nukiwa T; Watanabe A
    Tohoku J Exp Med; 1998 Sep; 186(1):67-70. PubMed ID: 9915109
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Susceptibility of methicillin-resistant Staphylococcus aureus clinical isolates to various antimicrobial agents. II. Isolation of arbekacin-resistant strain.
    Inouye Y; Morifuji K; Masumi N; Nakamura S; Takesue Y; Santou T; Yokoyama T
    Hiroshima J Med Sci; 1992 Dec; 41(4):79-85. PubMed ID: 1293073
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinical efficacy of arbekacin in deep MRSA infection. Including follow-up study after the termination of chemotherapy].
    Kuwabara M; Konishi F; Yokoyama T; Kodama T; Santoh T; Nakai S; Miyoshi N; Kurimura T; Miyazawa T; Arita K
    Jpn J Antibiot; 1994 Jun; 47(6):771-80. PubMed ID: 8072186
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Antibacterial activity of various antibacterial agents against methicillin-resistant Staphylococcus aureus, and difference in antibacterial activity between aminoglycosides by coagulase type. Comparison of isolates obtained in the period from 1982 to 1986 and isolates in recent 6 months].
    Wada K; Kawasima T; Arakawa M; Ozaki K
    Jpn J Antibiot; 1990 Feb; 43(2):219-27. PubMed ID: 2362349
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Efficacy of arbekacin, a new aminoglycoside antibiotic, in surgical patients with MRSA infections].
    Ishikawa S; Yura J; Shinagawa N; Mizuno A; Mashita K; Hori K
    Jpn J Antibiot; 1994 Jun; 47(6):820-5. PubMed ID: 8072192
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Vancomycin and arbekacin, drugs of treatment for MRSA infections].
    Kobayashi Y
    Nihon Rinsho; 1992 May; 50(5):1054-9. PubMed ID: 1507428
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
    Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effects of a combination therapy consisting of arbekacin and ampicillin of methicillin-resistant Staphylococcus aureus].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Suzuki K; Fukayama S; Ishihara R; Oda S
    Jpn J Antibiot; 1993 Jan; 46(1):8-17. PubMed ID: 8455335
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Takanashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Kosakai N; Yamaguchi K; Matsumoto T; Kashitani F; Tanaka M
    Jpn J Antibiot; 1997 Mar; 50(3):219-50. PubMed ID: 9575353
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The in vitro antibacterial activity of cefozopran against clinically isolated bacteria].
    Higurashi Y; Okuzumi K; Yoneyama A; Nakahara K
    Jpn J Antibiot; 1997 Dec; 50(12):907-16. PubMed ID: 9545668
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A possible immunomodulating activity of arbekacin (ABK), a newly synthesized antibiotic against methicillin-resistant Staphylococcus aureus (MRSA).
    Okai Y; Ishizaka S
    Int J Immunopharmacol; 1994 Apr; 16(4):321-7. PubMed ID: 8045672
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Arbekacin resistant gene, aacA/aphD, in Staphylococcus aureus is lost during in vitro passage].
    Chen G; Fukuchi K; Wakuta R; Kubo S; Yasuhara T; Takagi Y; Gomi K
    Rinsho Byori; 2002 Jan; 50(1):79-84. PubMed ID: 11871141
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2002)].
    Shimada K; Nakano K; Igari J; Oguri T; Ikemoto H; Mori T; Yokouchi H; Yamamoto M; Inoue H; Nakadate T; Suwabe A; Okada S; Ashino Y; Gejyo F; Okada M; Aoki N; Kitamura N; Suzuki Y; Karasawa Y; Nakata K; Nakatani T; Inagawa H; Kudo K; Kobayashi N; Tanaka T; Kobayashi H; Goto H; Kawai S; Takeda H; Sumitomo M; Matsushima T; Niki Y; Kohno S; Miyazaki Y; Yanagihara K; Hirakata Y; Matsuda J; Nasu M; Hiramatsu K; Suga M; Tosaka M
    Jpn J Antibiot; 2004 Jun; 57(3):213-45. PubMed ID: 15376784
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Efficacy of combination therapy against MRSA in Ibaraki Prefecture].
    Otsuka M; Sawahata T; Nakai T; Hasegawa S; Iwata S; Yoshizawa Y; Ishida H; Irokawa M; Goto A; Shinohara Y
    Jpn J Antibiot; 1994 Jun; 47(6):781-9. PubMed ID: 8072187
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dosage regimen of arbekacin for methicillin-resistant Staphylococcus aureus infection in newborns and infants.
    Yoshida K; Minowa H; Ebisu R; Uchida Y; Takahashi Y; Yoshioka A
    Pediatr Int; 2004 Dec; 46(6):645-9. PubMed ID: 15660861
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Drug resistance of methicillin-resistant Staphylococcus aureus (MRSA) in Japan until 1993].
    Hashimoto H
    Jpn J Antibiot; 1994 Jun; 47(6):575-84. PubMed ID: 8072165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.